Metabolic biomarkers for predicting responsiveness to FGF-18 compound

• Main Authors: KARSDAL MORTEN, GUEHRING HANS, KVIST PER, BAY-JENSEN ANNERISTINE, LADEL CHRISTOPH H
• Format: Patent
• Language: Chinese; English
• Published: 15.05.2020
• Subjects: HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEDICAL OR VETERINARY SCIENCE; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; TESTING

The present invention relates to biomarkers associated with the clinical response to an FGF-18 compound before or during the treatment of a cartilage disorder. The present invention more particularlyrelates to specific proteins present in the blood, serum, synovial fluid or in the urine which can be used for the diagnosis and treatment of cartilage disorders. The invention further discloses specific proteins that are related to cartilage response to the FGF-18 compound treatment as well as diagnostic tools and kits based on their expression profile. Thus, the biomarkers can be used for predicting the response to the FGF-18 compound treatment, before starting the treatment with FGF-18 or during the treatment, it could be used for selecting/identifying subjects to be treated by intra- articular administration of the FGF-18 compound. The use of these biomarkers in diagnostics could result in increased benefit and reduced risk in subjects. 本发明涉及与软骨疾病治疗之前或期间FGF-18化合物临床反应相关的生物标志物。尤其，本发明涉及血液、血清、滑液或尿液中可用于诊断和治疗软骨疾病的特定